{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T06:28:49Z","timestamp":1773469729553,"version":"3.50.1"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"27","license":[{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,14]]},"DOI":"10.1093\/eurheartj\/ehac261","type":"journal-article","created":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T03:30:03Z","timestamp":1652153403000},"page":"2633-2635","source":"Crossref","is-referenced-by-count":4,"title":["Early-stage amyloid transthyretin cardiomyopathy: uncertainties and opportunities"],"prefix":"10.1093","volume":"43","author":[{"given":"Claudio","family":"Rapezzi","sequence":"first","affiliation":[{"name":"Cardiologic Centre, University of Ferrara , Ospedale di Cona, Via Aldo Moro 8, 44124 Cona (Ferrara) , Italy"},{"name":"Maria Cecilia Hospital, GVM Care & Research , Cotignola (Ravenna) , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Serenelli","sequence":"additional","affiliation":[{"name":"Cardiologic Centre, University of Ferrara , Ospedale di Cona, Via Aldo Moro 8, 44124 Cona (Ferrara) , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9129-9519","authenticated-orcid":false,"given":"Alberto","family":"Aimo","sequence":"additional","affiliation":[{"name":"Institute of Life Sciences, Scuola Superiore Sant\u2019Anna , Pisa , Italy"},{"name":"Cardiology Division, Fondazione Toscana Gabriele Monasterio , Pisa , Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,5,26]]},"reference":[{"key":"2022071323565155100_ehac261-B1","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"2022071323565155100_ehac261-B2","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1093\/eurheartj\/ehac259","article-title":"Characteristics and natural history of early-stage cardiac transthyretin amyloidosis","volume":"43","author":"Law","year":"2022","journal-title":"Eur Heart J"},{"key":"2022071323565155100_ehac261-B3","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"2022071323565155100_ehac261-B4","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1093\/eurheartj\/ehab609","article-title":"Longitudinal strain in the management of cardiac AL amyloidosis: do we need it?","volume":"43","author":"Rapezzi","year":"2022","journal-title":"Eur Heart J"},{"key":"2022071323565155100_ehac261-B5","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/ejhf.2113","article-title":"Use of biomarkers to diagnose and manage cardiac amyloidosis","volume":"23","author":"Castiglione","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2022071323565155100_ehac261-B6","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.bbrc.2011.04.133","article-title":"Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs","volume":"410","author":"Bourgault","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"2022071323565155100_ehac261-B7","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1001\/jama.2022.2896","article-title":"Association of transthyretin Val122Ile variant with incident heart failure among black individuals","volume":"327","author":"Parcha","year":"2022","journal-title":"JAMA"},{"key":"2022071323565155100_ehac261-B8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1056\/NEJMoa1404852","article-title":"The amyloidogenic V122I transthyretin variant in elderly black Americans","volume":"372","author":"Quarta","year":"2015","journal-title":"N Engl J Med"},{"key":"2022071323565155100_ehac261-B9","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.ahj.2010.02.006","article-title":"Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies","volume":"159","author":"Buxbaum","year":"2010","journal-title":"Am Heart J"},{"key":"2022071323565155100_ehac261-B10","doi-asserted-by":"crossref","first-page":"e13598","DOI":"10.1111\/eci.13598","article-title":"Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis","volume":"51","author":"Aimo","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"2022071323565155100_ehac261-B11","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2022071323565155100_ehac261-B12","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1161\/CIRCULATIONAHA.119.045093","article-title":"Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy","volume":"141","author":"Kazi","year":"2020","journal-title":"Circulation"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/27\/2633\/44858087\/ehac261.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/27\/2633\/44858087\/ehac261.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T23:57:19Z","timestamp":1657756639000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/43\/27\/2633\/6593473"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,26]]},"references-count":12,"journal-issue":{"issue":"27","published-online":{"date-parts":[[2022,5,26]]},"published-print":{"date-parts":[[2022,7,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehac261","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,14]]},"published":{"date-parts":[[2022,5,26]]}}}